2016
Attitudes toward medication-assisted treatment among fishermen in Kuantan, Malaysia, who inject drugs
Brown SE, Wickersham JA, Pelletier AR, Marcus RM, Erenrich R, Kamarulzaman A, Altice FL. Attitudes toward medication-assisted treatment among fishermen in Kuantan, Malaysia, who inject drugs. Journal Of Ethnicity In Substance Abuse 2016, 16: 363-379. PMID: 27404914, PMCID: PMC5592158, DOI: 10.1080/15332640.2016.1196632.Peer-Reviewed Original Research
2015
Treatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia
Vijay A, Bazazi AR, Yee I, Kamarulzaman A, Altice FL. Treatment Readiness, Attitudes Toward, and Experiences with Methadone and Buprenorphine Maintenance Therapy Among People Who Inject Drugs in Malaysia. Journal Of Substance Use And Addiction Treatment 2015, 54: 29-36. PMID: 25841703, PMCID: PMC4758679, DOI: 10.1016/j.jsat.2015.01.014.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAge of OnsetAgedAttitudeBuprenorphineEthnicityFemaleHumansMalaysiaMaleMethadoneMiddle AgedNarcoticsNeedle SharingNeedle-Exchange ProgramsOpiate Substitution TreatmentPatient Acceptance of Health CareStress, PsychologicalSubstance Abuse Treatment CentersSubstance Abuse, IntravenousYoung AdultConceptsOpioid maintenance therapyBuprenorphine maintenance therapyMaintenance therapyTreatment readinessNeedle/syringe exchange programsSharing of needlesMultivariable linear regressionSyringe exchange programsCompulsory drug detention centersMajority of subjectsReadiness scoresOpioid dependencePatients' attitudesPrimary careMethadoneTreatment settingsStress symptom severityBuprenorphineIndian ethnicityAdult populationSymptom severityOlder agePast monthTherapyDrugs
2011
Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence
Saber-Tehrani AS, Bruce RD, Altice FL. Pharmacokinetic drug interactions and adverse consequences between psychotropic medications and pharmacotherapy for the treatment of opioid dependence. The American Journal Of Drug And Alcohol Abuse 2011, 37: 1-11. PMID: 21247284, DOI: 10.3109/00952990.2010.540279.Peer-Reviewed Original ResearchConceptsPharmacokinetic drug interactionsDrug interactionsOpioid dependencePsychotropic medicationsPsychoactive medicationsImportant pharmacokinetic drug interactionsClasses of medicationsOpioid-dependent patientsRelevant English-language articlesClinical case seriesMedication-assisted treatmentCytochrome P450 isoenzymesImportant clinical consequencesEnglish-language articlesPharmacokinetic interaction studyCase seriesPsychiatric comorbidityEmbase databasesClinical consequencesMedicationsP450 isoenzymesBuprenorphineMethadoneLanguage articlesPsychoactive drugs
2009
Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market
Bruce RD, Govindasamy S, Sylla L, Kamarulzaman A, Altice FL. Lack of Reduction in Buprenorphine Injection After Introduction of Co-Formulated Buprenorphine/Naloxone to the Malaysian Market. The American Journal Of Drug And Alcohol Abuse 2009, 35: 68-72. PMID: 19212931, PMCID: PMC2791788, DOI: 10.1080/00952990802585406.Peer-Reviewed Original ResearchConceptsBuprenorphine/naloxoneOpioid withdrawal symptomsSyringe sharingWithdrawal symptomsSnowball recruitment techniquesLogistic regression analysisDiversion of buprenorphineLack of reductionEvidence-based approachPrimary outcomeBuprenorphine injectionOnly symptomBenzodiazepine useBenzodiazepine injectionStomach painBuprenorphineInjection doseRisk behaviorsSymptomsNaloxoneInjectionRegression analysisNLXDaily amountDose
2008
Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia
Bruce RD, Govindasamy S, Sylla L, Haddad MS, Kamarulzaman A, Altice FL. Case Series of Buprenorphine Injectors in Kuala Lumpur, Malaysia. The American Journal Of Drug And Alcohol Abuse 2008, 34: 511-517. PMID: 18584580, DOI: 10.1080/00952990802122259.Peer-Reviewed Original ResearchConceptsBuprenorphine injectionBuprenorphine injectorsCase seriesSignificant adverse health consequencesProspective cohort studyPossible pharmacological interactionsAdverse health consequencesDiversion of buprenorphineCohort studyResultant symptomsPoor outcomeCase reportTreatment modalitiesPharmacological interactionsBuprenorphineEuphoric effectsHealth consequencesKuala LumpurMidazolamInjectionQualitative interviewsSymptoms
2007
HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications
Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine—programme description and policy implications. International Journal Of Drug Policy 2007, 18: 326-328. PMID: 17689382, PMCID: PMC2084072, DOI: 10.1016/j.drugpo.2006.12.011.Peer-Reviewed Original ResearchConceptsBuprenorphine maintenance therapyInjection drug useAnti-retroviral therapySubstitution therapyDrug useAddition of methadoneAdministration of buprenorphineHIV-1 seropositivityOpiate substitution therapyOverall health outcomesIllicit drug useCost of buprenorphineHIV treatment accessMaintenance therapyOpioid dependenceHIV casesEntry criteriaTreatment accessBuprenorphineDrug usersHealth outcomesMultidisciplinary teamTherapyGlobal Fund resourcesAdministrationCase Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases
Bruce RD, Altice FL. Case Series on the Safe Use of Buprenorphine/Naloxone in Individuals with Acute Hepatitis C Infection and Abnormal Hepatic Liver Transaminases. The American Journal Of Drug And Alcohol Abuse 2007, 33: 869-874. PMID: 17994482, DOI: 10.1080/00952990701653875.Peer-Reviewed Original ResearchConceptsHepatitis C virusAcute hepatitis C infectionHepatitis C infectionBuprenorphine treatmentC infectionChronic viral illnessesSafety of buprenorphineAcute HCV infectionBuprenorphine/naloxoneOpiate substitution therapyOpioid-dependent patientsOpiate substitution treatmentLaboratory evaluationChronic hepatitisElevated transaminasesHCV infectionLiver transaminasesViral illnessCase seriesSubstitution therapyC virusSubstitution treatmentBuprenorphinePatientsTransaminasePharmacological Treatment of Substance Abuse in Correctional Facilities: Prospects and Barriers to Expanding Access to Evidence-Based Therapy
Bruce R, Smith-Rohrberg D, Altice F. Pharmacological Treatment of Substance Abuse in Correctional Facilities: Prospects and Barriers to Expanding Access to Evidence-Based Therapy. 2007, 385-411. DOI: 10.1007/978-0-387-71695-4_23.Peer-Reviewed Original ResearchPharmacological treatmentSubstance abuseSerious public health concernEvidence-based therapiesTreatment of cocainePublic health concernCorrectional health careAvailable medicationsMethamphetamine abuseHealth concernNew drugsHealth careChemical dependencyTreatmentIncarcerated populationsAbuseCorrectional facilitiesMedicationsBuprenorphinePharmacotherapyNaltrexoneMethadoneTherapyDisulfiramCareBehavioral Counseling Content for Optimizing the Use of Buprenorphine for Treatment of Opioid Dependence in Community-Based Settings: A Review of the Empirical Evidence
Copenhaver MM, Bruce RD, Altice FL. Behavioral Counseling Content for Optimizing the Use of Buprenorphine for Treatment of Opioid Dependence in Community-Based Settings: A Review of the Empirical Evidence. The American Journal Of Drug And Alcohol Abuse 2007, 33: 643-654. PMID: 17891657, PMCID: PMC2274830, DOI: 10.1080/00952990701522674.Peer-Reviewed Original Research
2006
The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention
Altice FL, Sullivan LE, Smith-Rohrberg D, Basu S, Stancliff S, Eldred L. The Potential Role of Buprenorphine in the Treatment of Opioid Dependence in HIV-Infected Individuals and in HIV Infection Prevention. Clinical Infectious Diseases 2006, 43: s178-s183. PMID: 17109304, DOI: 10.1086/508181.Peer-Reviewed Original ResearchMeSH KeywordsBuprenorphineDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHIV InfectionsHumansIncidenceMaleNarcotic AntagonistsOpioid-Related DisordersRisk AssessmentSeverity of Illness IndexSubstance Abuse DetectionSubstance Abuse Treatment CentersSurvival AnalysisTreatment OutcomeUnited StatesConceptsHIV clinical care settingsHIV treatment outcomesClinical care settingsRole of buprenorphineOpioid dependenceTreatment outcomesCare settingsHuman immunodeficiency virus (HIV) infectionStudies of buprenorphineImmunodeficiency virus infectionHIV infection preventionUntreated opioid dependenceAntiretroviral therapyHIV carePreventive therapySecondary preventionAntiretroviral treatmentBuprenorphine treatmentHIV infectionOpportunistic infectionsSuccessful treatmentInfection preventionVirus infectionBuprenorphineInfected individualsThree case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir
Bruce RD, Altice FL. Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir. AIDS 2006, 20: 783-784. PMID: 16514314, DOI: 10.1097/01.aids.0000216384.22432.9a.Peer-Reviewed Original Research
2004
Research Note — Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations
Smith-Rohrberg D, Bruce R, Altice F. Research Note — Review of Corrections-Based Therapy for Opiate-Dependent Patients: Implications for Buprenorphine Treatment among Correctional Populations. Journal Of Drug Issues 2004, 34: 451-480. DOI: 10.1177/002204260403400210.Peer-Reviewed Original ResearchOpiate dependencePharmacological treatment optionsEmergency room usePrimary care servicesOpiate-dependent patientsCommunity-based treatmentInfectious disease prevalenceBuprenorphine treatmentNote reviewTreatment optionsOpiate useCorrectional populationsDrug AdministrationRecent approvalCare servicesDisease prevalenceRoom useSubstantial proportionTreatmentCorrectional settingsDesirable healthBuprenorphinePatientsTherapyPopulation